DrugPatentWatch Database Preview
DEXILANT Drug Profile
Which patents cover Dexilant, and what generic alternatives are available?
Dexilant is a drug marketed by Takeda Pharms Usa and is included in two NDAs. There are twenty-one patents protecting this drug and two Paragraph IV challenges.
The generic ingredient in DEXILANT is dexlansoprazole. There are seventeen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dexlansoprazole profile page.
Summary for DEXILANT
| US Patents: | 15 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 41 |
| Clinical Trials: | 16 |
| Patent Applications: | 104 |
| Drug Prices: | Drug price information for DEXILANT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DEXILANT |
| DailyMed Link: | DEXILANT at DailyMed |
Pharmacology for DEXILANT
| Drug Class | Proton Pump Inhibitor |
| Mechanism of Action | Proton Pump Inhibitors |
Medical Subject Heading (MeSH) Categories for DEXILANT
Synonyms for DEXILANT
| (+)-(R)-Lansoprazole |
| (+)-2-((R)-{(3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl}sulfinyl)-1H-benzimidazole |
| (+)-lansoprazol |
| (r)-(+)-lansoprazole |
| (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzimidazole |
| (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| (R)-2-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYLSULFINYL)-1H-BENZO[D]IMIDAZOLE |
| (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole |
| (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]benzimidazole |
| (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole |
| (R)-Lansoprazole |
| 138530-94-6 |
| 1H-Benzimidazole, 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)- |
| 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole |
| 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole |
| 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole |
| 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanesulfinyl]-1H-1,3-benzodiazole |
| 2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methane}sulfinyl]-1H-1,3-benzodiazole |
| 3B1-001176 |
| AB01563023_01 |
| AB01563023_02 |
| AC-26449 |
| AK170558 |
| AKOS025290765 |
| AN-31849 |
| AS-18086 |
| CCG-213301 |
| CHEBI:135931 |
| CHEMBL1201863 |
| CS-2820 |
| D06YYD |
| D08903 |
| DB05351 |
| Dexilant Solutab |
| dexlansoprazole |
| Dexlansoprazole (INN/USAN) |
| Dexlansoprazole [USAN:INN] |
| Dexlansoprazole sesquihydrate |
| FT-0670721 |
| GTPL5487 |
| HE065042 |
| HMS3652C14 |
| HY-13662B |
| Kapidex |
| KS-00000PLS |
| KS-1075 |
| MFCD13196699 |
| MJIHNNLFOKEZEW-RUZDIDTESA-N |
| MolPort-002-885-834 |
| PB33188 |
| Q-1374 |
| R- -Lansoprazole |
| R-(+)-LANSOPRAZOLE |
| r-lansoprazole |
| s4099 |
| SC-71768 |
| SCHEMBL44975 |
| T 168390 |
| T-168390 |
| TAK 390 |
| TAK-390 |
| TAK-390MR |
| UNII-0K5C5T2QPG component MJIHNNLFOKEZEW-RUZDIDTESA-N |
| UNII-UYE4T5I70X |
| UYE4T5I70X |
| W0028 |
| ZINC599734 |
US Patents and Regulatory Information for DEXILANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | DEXILANT SOLUTAB | dexlansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 208056-001 | Jan 26, 2016 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for DEXILANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for DEXILANT
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for DEXILANT
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2013106514 | ➤ Sign Up |
| Japan | 4160293 | ➤ Sign Up |
| Australia | 2008310735 | ➤ Sign Up |
| Peru | 01022005 | ➤ Sign Up |
| China | 100562317 | ➤ Sign Up |
| China | 1571659 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006090845 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for DEXILANT
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1129088/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: DEXLANSOPARAZOL; REGISTRATION NO/DATE: SWISSMEDIC 62993 09.05.2014 |
| 2014014,C1129088 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEXLANSOPRAZOLUM; REGISTRATION NO/DATE: LT/1/13/3415/001 - LT/1/13/3415/004, 2013 10 31 LT/1/13/3416/001 - LT/1/13/3416/004 20131031 |
| 2014000036 | Germany | ➤ Sign Up | PRODUCT NAME: KRISTALLINE FORM DES (R)-2-(((3-METHYL-4-(2,2,2-TRIFLUORETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAOLS; NAT. REGISTRATION NO/DATE: 87192.00.00 87193.00.00 87194.00.00 87195.00.00 20131118 FIRST REGISTRATION: SCHWEDEN 47911 47912 47913 47914 20130919 |
| 90004-7 | Sweden | ➤ Sign Up | PRODUCT NAME: DEXLANSOPRAZOL; REG. NO/DATE: 47912, 47913, 47914 20130919 |
| 2014014 | Lithuania | ➤ Sign Up | PRODUCT NAME: DEXLANSOPRAZOLUM; REGISTRATION NO/DATE: LT/1/13/3415/001 - LT/1/13/3415/004, 2013 10 31 LT/1/13/3416/001 - LT/1/13/3416/004 20131031 |
| 14/008 | Ireland | ➤ Sign Up | PRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
